Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity

Drug Metabolism Reviews

Volumn 40, Issue 2, 2008, Pages 303-315

  Auman, J Todd ^a   McLeod, Howard L ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

Chemosensitivity; DNA polymorphisms; Gene expression profiling; Genotype; Microarray; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CISPLATIN; DNA; DOCETAXEL; FLUOROURACIL; IRINOTECAN; RNA; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN;

ABCB1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; BLADDER CARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CHEMOSENSITIVITY; CYP2D6 GENE; EGFR GENE; GENE; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTYPE; GSTM1 GENE; HUMAN; MDR1 GENE; MICROARRAY ANALYSIS; MTHFR GENE; PHARMACOGENOMICS; PHENOTYPE; REVIEW; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TYMS GENE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; NEOPLASM; PATIENT SELECTION; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 44649098271     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530801952427     Document Type: Review

References (50)

1. Bieche, I., Laurendeau, I., Tozlu, S., Olivi, M., Vidaud, D., Lidereau, R., and Vidaud, M. (1999). Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 59:2759-2765.
2. Bild, A. H., Yao, G., Chang, J. T., Wang, W., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., Olson, J. A., Marks, J. R. Dressman, H. K., West, M., and Nevins, J. R. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
3. Borgna, J. L. and Rochefort, H. (1981). Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256:859-868.
4. Bussey, K. J., Chin, K., Lababidi, S., Reimers, M., Reinhold, W. C., Kuo, W.-L., Gwadry, F., Ajay, F., Kouros-Mehr, H., Fridlyand, J., Jain, A., Collins, C., Nishizuka, S., Tonon, G. Roschke, A., Gehlhaus, K., Kirsch, I., Scudiero, D. A., Gray, J. W., and Weinstein, J. N. (2006). Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5:853-867.
5. Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., Harris, A., Bogaerts, J., Therasse, P., Floore, A., Amakrane, M., Piette, F., Rutgers, E., Sotiriou, C., Cardoso, F., and Piccart, M. J. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with nodenegative breast cancer. J. Natl. Cancer Inst. 98:1183-1192.
6. Capizzi, R. L., Bertino, J. R., and Handschumacher, R. E. (1970). L-asparaginase. Annu. Rev. Med. 21:433-444.
7. Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Elledge, R., Mohsin, S., Osborne, C. K., Chamness, G. C., Allred, D. C., and O'Connell, P. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369.
8. Cooney, D. A. and Handschumacher, R. E. (1970). L-asparaginase and L-asparagine metabolism. Annu. Rev. Pharmacol. 10:421-440.
9. Cronin, M., M. Pho, M., Dutta, D., Stephans, J. C., S. Shak, S., Kiefer, M. C., Esteban, J. M., and Baker, J. B. (2004). Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol. 164:35-42.
10. Desta, Z., Ward, B. A., Soukhova, N. V., and Flockhart, D. A. (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310:1062-1075.
11. Dolan, M. E., Newbold, K. G., Nagasubramanian, R., Wu, X., Ratain, M. J., Cook, Jr., E. H., and Badner, J. A. (2004). Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64: 4353-4356.
12. Early Breast Cancer Trialists' Collaboration Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717.
13. Glas, A. M., Floore, A., Delahaye, L. J., Witteveen, A. T., Pover, R. C., Bakx, N, Lahti-Domenici, J. S., Bruinsma, T. J., Warmoes, M. O., Bernards, R., Wessels, L. F., and Van't Veer, L. J. (2006). Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7:278.
14. Goekkurt, E., Hoehn, S., Wolschke, C., Wittmer, C., Stueber, C., Hossfeld, D. K., and J. Stoehlmacher, J. (2006). Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 94: 281-286.
15. Goetz, M. P., Kamal, A., and Ames, M. M. (2007). Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther. (In press, DOI: 10.1038/ sj.clpt.6100367).
16. Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Weinshilboum, R. M., Fritcher, E. G., Nibbe, A. M., Desta, Z., Nguyen, A., Flockhart, D. A., Perez, E. A., and Ingle, J. N. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101:113-121.
17. Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., Desta, Z., Perez, E. A., and Ingle, J. N. (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23:9312-9318.
18. Horie, N., Aiba, H., Oguro, K., Hojo, H., and Takeishi, K. (1995). Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20:191-197.
19. Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J. F., Hoctin-Boes, G., Houghton, J., Locker, G. Y., and Tobias, J. S. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62.
20. Huang, R. S., Duan, A., Shukla, S. J., Kistner, E. O., Clark, T. A., Chen, T. X., Schweitzer, A. C., Blume, J. E., and Dolan, M. E. (2007). Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81:427-437.
21. Ingle, J. N., Suman, V. J., Mailliard, J. A., Kugler, J. W., Krook, J. E., Michalak, J. C., Pisansky, T. M., Wold, L. E., Donohue, J. H., Goetz, M. P., and Perez, E. A. (2006). Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res. Treat. 98:217-222.
22. Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K. H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., Blanchard, R., Nguyen, A., Ullmer, L., Hayden, J., Lemler, S., Weinshilboum, R. M., Rae, J. M., Hayes, D. F., and Flockhart, D. A. (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97:30-39.
23. Johnson, M. D., H. Zuo, H., K. H. Lee, K. H., J. P. Trebley, J. P. J. M. Rae, J. M. R. V. Weatherman, Desta, Z., Flockhart, D. A., and Skaar, T. C. (2004). Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85:151-159.
24. Johnston, P. G., Mick, R., Recant, W., Behan, K. A., Dolan, M. E., Ratain, M. J., Beckmann, E., Weichselbaum, R. R., Allegra, C. J., and Vokes, E. E. (1997). Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J. Natl. Cancer Inst. 89:308-313.
25. Kawakami, K., Omura, K., Kanehira, E., and Watanabe, Y. (1999). Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19:3249-3252.
26. Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., and Halmos, B. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352:786-792.
27. Kristiansen, G., Yu, Y., Petersen, S., Kaufmann, O., Schluns, K., Dietel, M., and Petersen, I. (2001). Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur. J. Cancer 37: 1089-1095.
28. Lee, J. K., Havaleshko, D. M., Cho, H., Weinstein, J. N., Kaldjian, E. P., Karpovich, J., Grimshaw, A., and Theodorescu, D. (2007). A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA 104:13086-13091.
29. Lim, H.-S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.-J. and Ro, J. (2007). Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25:3837-3845.
30. Lonning, P. E., Lien, E. A., Lundgren, S., and Kvinnsland, S. (1992). Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin. Pharmacokinet. 22: 327-358.
31. Lynch, T. J., Bell, D. W., Sordella, R, Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., and Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129-2139.
32. Ma, X. J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., Tran, Y., Tran, D., A. Tassin, A., Amon, P., Wang, W., Wang, W., Enright, E., Stecker, K., Estepa-Sabal, E., Smith, B., Younger, J., Balis, U., J. Michaelson, J., Bhan, A., Habin, K., Baer, T. M., J. Brugge, J., Haber, D. A., Erlander, M. G., and Sgroi, D. C. (2004). A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616.
33. Martin, Y. N., Salavaggione, O. E., Eckloff, B. W., Wieben, E. D., Schaid, D. J., and Weinshilboum, R. M. (2006). Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet. Genomics 16:265-277.
34. Mathijssen, R. H., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., and McLeod, H. L. (2003). Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9:3246-3253.
35. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J., and Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351:2817-2826.
36. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., Costantino, J. P., Geyer, Jr., C. E., Wickerham, D. L., and Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24:3726-3734.
37. Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., Harpole, D., Marks, J., Berchuck, A., Ginsburg, G. S., Febbo, P., Lancaster, J., and Nevins, J. R. (2006). Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12:1294-1300.
38. Pui, C.-H. and Evans, W. E. (1998). Acute Lymphoblastic Leukemia. .N Engl. J. Med. 339:605-615.
39. Pui, C.-H., J. T. Sandlund, J. T., D. Pei, D., D. Campana, D., G. K. Rivera, G. K., R. C. Ribeiro, R. C., J. E. Rubnitz, J. E., B. I. Razzouk, B. I., S. C. Howard, S. C., M. M. Hudson, M. M., C. Cheng, C., L. E. Kun, L. E., S. C. Raimondi, S. C., F. G. Behm, F. G., Downing, J. R., Relling, M. V., and Evans, W. E. (2004). Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104:2690-2696.
40. Pui, C. H., Gaynon, P. S., Boyett, J. M., Chessells, J. M., Baruchel, A., Kamps, W., Silverman, L. B., Biondi, A., Harms, D. O., Vilmer, E., Schrappe, M., and Camitta, B. (2002). Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915.
41. Rocha, J. C. C., Cheng, C., Liu, W., Kishi, S. Das, S., Cook, E. H., Sandlund, J. T., Rubnitz, J., Ribeiro, R., Campana, D., Pui, C.-H., Evans, W. E., and Relling, M. V. (2005). Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105:4752-4758.
42. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., Pergamenschikov, A., Lee, J. C. F., Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D., and Brown, P. O. (2000). Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-235.
43. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., Scudiero, D. A., Eisen, M. B., Sausville, E. A., Pommier, Y., Botstein, D., Brown, P. O., and Weinstein, J. N. (2000). A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24: 236-244.
44. Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., Mesirov, J. P., Lander, E. S., and Golub, T. R. (2001). Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 98:10787-10792.
45. Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava, P., Hayes, D. F., Desta, Z., and Flockhart, D. A. (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95:1758-1764.
46. Thurlimann, B., Keshaviah, A., Coates, A. S., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, M., Gelber, R. D., Rabaglio, M., Smith, I., Wardley, A., Price, K. N., and Goldhirsch, A. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353: 2747-2757.
47. Townsend, D. M. and Tew, K. D. (2003). The role of glutathione-S- transferase in anti-cancer drug resistance. Oncogene 22:7369-7375.
48. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., M. Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., K. R.M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
49. van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., Parrish, M, Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E. T., Friend, S. H., and Bernards, R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009.
50. Watters, J. W., Kraja, A., Meucci, M. A., Province, M. A., and McLeod, H. L. (2004). Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl. Acad. Sci. USA 101:11809-11814.